Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2025

Conditions
Proliferative Diabetic Retinopathy
Interventions
DRUG

conbercept ophthalmic injection (0.5mg)

Participants were randomly assigned to receive intravitreal injections of either faricimab (IVF, n=4) or conbercept (IVC, n=4) based on a randomisation protocol. To establish a baseline comparison, FVMs were obtained from three treatment-naive patients who served as controls. All participants underwent surgery 4 days after the intravitreal anti-VEGF injections.

DRUG

Faricimab

According to the randomization protocol, participants were randomly assigned to receive intravitreal injections of faricimab (IVF, n=4) or conbercept (IVC, n=4). To establish a baseline comparison, FVMs were obtained from three treatment-naïve patients as controls. All participants underwent surgery 4 days after intravitreal anti-VEGF injection.

Trial Locations (1)

300000

Tianjin medical university eye hosipital, Tianjin

All Listed Sponsors
lead

Bojie Hu

OTHER

NCT07144865 - Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection | Biotech Hunter | Biotech Hunter